OGN (Organon) Insider Ownership: 0.49 % (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OGN Organon & Co OGN
71 GF Score
Price $13.60
GF Value $13.38
Valuation Fairly Valued
! 11 Warning Signs
View Full Analysis

What is Organon Insider Ownership?

Organon OGN +0.37% 71 Insider Ownership is 0.49 % as of Aug. 08, 2026. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $13.38 (Fairly Valued). The stock has 11 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Organon's insider ownership is 0.49%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Organon's Institutional Ownership is 75.58%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Organon's Float Percentage Of Total Shares Outstanding is 87.97%.

Organon Insider Ownership Historical Data

* Premium members only.

The historical data trend for Organon's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organon Insider Ownership Chart

Organon Historical Data

The historical data trend for Organon can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 0.37 0.37 0.37 0.37 0.38 0.38 0.38 0.49 0.49 0.49
OGN
71GF Score
Organon & Co OGN
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organon Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.49 % mean?
Organon (OGN) has a Insider Ownership of 0.49 % as of Aug. 08, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Organon and its competitors.
Is Organon's Insider Ownership too high?
Organon's current Insider Ownership is 0.49 %. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Insider Ownership compare to AMRN and SCLX?
Organon's Insider Ownership of 0.49 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Organon and its competitors. Organon's current Insider Ownership is 0.49 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $13.38, compared to a current price of $13.60 — trading 1.6% above its estimated fair value. The current Insider Ownership is 0.49 %. Organon's overall GF Score™ is 71/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Organon (OGN), the current Insider Ownership is 0.49 % as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organon (OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be overvalued. The current stock price of $13.60 is trading 1.6% above its estimated GF Value™ of $13.38. GuruFocus considers Organon to be Fairly Valued.

Key valuation signals for OGN:

  • Insider Ownership: 0.49 %
  • GF Value™: $13.38 vs. price of $13.60 (1.6% above fair value)
  • GF Score™: 71/100 with 11 warning signs

No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score

Get the complete analysis for OGN

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.60
Price
$13.38
GF Value